Market not understanding just how consequential this is. $CBRS
This quoted post is unavailable.
3
768
$PODD down again on Truist downgrade. I always wonder who sells on SS downgrades. The stock is down 60% … this stuff is all already understood. Did anyone really need Truist to tell them that more competition wa coming to this space?
2
284
Here’s why markets are so F’ing hard: $PODD is sort of an obvious short. Massive growth decel. Continuous quarters of guidance cuts. CEO that frankly appears clueless like a deer in the headlights. Incoming competitors in tubeless insulin that challenge their tech superiority
1
246
20%+ earnings growth here to a nice mid-to-high teens IRR. Long $PODD.
66
Curious, Adam. Thoughts on your thesis after the very disappointing $ZURA data? it appears sonelokimab may have the edge after all here and is likely to be given priority review by FDA. An update to your thesis would be appreciated
Replying to @A_May_MD
Slide 5: Debunking the myth of IL17*F* Part 4
The next examples of *clinical* data that debunk the importance of hitting IL17F are the $MLTX Sonelokimab sagas.
Sonelokimab was the much-hyped IL17 inhibitor developed by Moonlake Therapeutics. It was supposed to be a fast-follower to Bimzelx with “me-better” potential. Why? Sonelokimab had ~6x higher IL17FF affinity than Bimzelx!
The logic here was simple: If hitting IL17F is what set Bimelx apart as the best IL17 inhibitor, then a drug that hits IL17F *even harder* would be even BETTER! Right?!
Well, not only did Sonelokimab yield lower efficacy in psoriasis than Bimzelx, it even yielded lower efficacy than Taltz that doesn’t hit IL17F at all! And that isn’t even adjusting Taltz to the higher dose used in IXORA-P…
Then, in HS sonelokimab actually *missed* in one of its two phase 3 trials! Now, some of this was just bad luck for sonelokimab. It is *definitely* active because it does hit IL17A quite well. However, its IL17F affinity being GREATER than its IL17A affinity may have ultimately been a *disadvantage* instead of the advantage the market thought it would be. I wonder if highly abundant IL17F actually acted as a drug sink for sonelokimab and hindered its ability to cause maximal suppression of 17A.
In any case, the $MLTX/Sonelokimab case study showed us this: Maximizing IL17F affinity did NOT yield a better IL17 inhibitor…if anything, it gave us a *worse* one. This is yet another piece of clinical evidence pointing us *away* from hitting 17F and *toward* 17A, like $ZURA is going to do with Tibulizumab.
1
1
523
statements like “miracle for me”, “I can’t wait for this to hit the market”, “two words - life changing”, “absolutely incredible results”, “24 hours after my injection I noticed both flares have gone down significantly”, “it actually looks promising” $MLTX
1
2
306
“it was like magic for me”, “I finally feel some relief”, “I saw much more improvement very quickly after that started” $MLTX … hard to imagine denying patients this medication … excited for a priority review decision this or next week.
2
320
imminent with very defined upcoming catalysts including BLA acceptance in HS within the next 2 wks, phase 3 initiation of sonelokimab in PPP within 3 wks, phase 2 POLARIS in early ‘27, topline phase 3 IZAR-2 in early ‘27 … just absolutely loaded for $500m EV. No brainer $MLTX
1
181
I stand with Jensen here. His company. His vision. Shareholders love him. Employees love him. Board has no right to remove the man at the destruction of shareholder value. Put it to a vote. Typical corporate rule book does not apply here. #IStandWithJensen
4
299
✅ bottom appears to be in here. $SGI green on a bad print as the market better appreciates that they continue to take share. Falling 10yr helpful
This quoted post is unavailable.
1
371











